Gossamer Bio GOSS 深 滬
等待開盤 09-20 09:30:00 美东时间
0.9598
+0.049
+5.35%
華盛通- 最 高0.978
- 今 開0.94
- 成交量 64.27万股
- 最 低 0.9012
- 昨 收 0.9111
- 總市值 2.17亿
- 52周最高 1.60
- 市盈率 靜 --
- 換手率 0.28%
- 52周最低 0.4525
- 委 比 -86.54%
- 總股本 2.26亿
- 歷史最高 27.15
- 量 比 0.77
- 振 幅 8.43%
- 歷史最低 0.4525
- 每 手 1
- 風險率 0.24%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Bullish Outlook on Gossamer Bio’s Seralutinib Efficacy and Market Potential
Analyst Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Gossam...
09-17 21:35
Gossamer Bio Q2 2024 GAAP EPS $0.22 Beats $0.16 Estimate, Sales $95.842M Miss $114.286M Estimate
Gossamer Bio (NASDAQ:GOSS) reported quarterly earnings of $0.22 per share which beat the analyst consensus estimate of $0.16 by 37.5 percent. The company reported quarterly sales of $95.842 million which missed the
08-13 04:04
快讯 | gossamer bio宣布2024年第二季度财务业绩，并提供业务更新
Gossamer Bio Announces Second Quarter 2024 Financial Results and Provides Busin...
08-13 04:01
Top 3 Materials Stocks That May Explode In Q2
The most oversold stocks in the materials sector presents an opportunity to buy...
06-26 19:56
美股牛股 | Regis暴涨近305%！再融资后负债减少了8000万美元；比特数字升近40%
Regis暴涨近305%！公司再融资后负债减少8000万美元；比特数字涨近40%，公司宣布与重要HPC客户的合同扩展的最终条款>>
06-26 18:46
Gossamer Bio's Clean Safety Profile Differentiates It From Merck, Analyst Says
Oppenheimer initiated coverage on Gossamer Bio, highlighting seralutinib's clean long-term safety profile for pulmonary arterial hypertension. Seralutinib shows potential in underserved markets.
06-26 02:39
Recursion Pharmaceuticals Stock Is Moving Tuesday: What's Happening?
Shares of clinical stage biotech company Recursion Pharmaceuticals Inc (NASDAQ:RXRX) are trading higher Tuesday. The company's CEO Chris Gibson joined CNBC for an interview ahead of a presentation with Nvidia Corp's (NASDAQ:NVDA) Jensen Huang late Monday.
06-25 21:23
快讯 | 高丝生物公司：Oppenheimer以强于市场预期的评级开始覆盖；目标价为9美元。
Gossamer Bio Inc : Oppenheimer Initiates Coverage With Outperform Rating; Targe...
06-25 20:21
Goldman Sachs Maintains Buy on Gossamer Bio, Maintains $8 Price Target
Goldman Sachs analyst Paul Choi maintains Gossamer Bio (NASDAQ:GOSS) with a Buy and maintains $8 price target.
06-18 00:45
